S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:INBX

Inhibrx - INBX Stock Forecast, Price & News

$27.25
+0.16 (+0.59%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.85
$28.43
50-Day Range
$17.49
$33.33
52-Week Range
$7.67
$45.99
Volume
374,502 shs
Average Volume
488,636 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.50

Inhibrx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
70.6% Upside
$46.50 Price Target
Short Interest
Bearish
15.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
0.00mentions of Inhibrx in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$40 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.25) to ($3.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

398th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

66th out of 171 stocks

INBX stock logo

About Inhibrx (NASDAQ:INBX) Stock

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

INBX Stock News Headlines

Why Is Inhibrx (INBX) Stock Soaring 45% Today?
See More Headlines
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

INBX Company Calendar

Last Earnings
11/09/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.50
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+70.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-81,770,000.00
Net Margins
-2,628.82%
Pretax Margin
-2,628.74%

Debt

Sales & Book Value

Annual Sales
$7.23 million
Book Value
$1.38 per share

Miscellaneous

Free Float
32,315,000
Market Cap
$1.19 billion
Optionable
Not Optionable
Beta
3.08

Key Executives

  • Mr. Mark Paul LappeMr. Mark Paul Lappe (Age 55)
    Founder, Chairman, Pres & CEO
    Comp: $994.28k
  • Dr. Brendan P. Eckelman Ph.D.Dr. Brendan P. Eckelman Ph.D. (Age 43)
    Founder & Chief Scientific Officer
    Comp: $644.5k
  • Ms. Kelly Devine Deck B.S. (Age 42)
    CPA, M.S., Chief Financial Officer
    Comp: $423.75k
  • Mr. Quinn L. Deveraux
    Founder
  • Dr. Ashraf Amanullah (Age 54)
    Exec. VP & Chief Technical Operations Officer
  • Ms. Leah Pollema J.D.
    VP, Corp. Sec. & Gen. Counsel
  • Mr. Jeffrey J. JensenMr. Jeffrey J. Jensen
    EVP & Chief Clinical Devel. Officer
  • Mr. David Matly M.B.A.
    Exec. VP & Chief Commercial Officer
  • Dr. Carlos Bais Ph.D.
    Exec. VP of Translational Sciences













INBX Stock - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INBX shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price forecast for 2023?

4 analysts have issued twelve-month price objectives for Inhibrx's shares. Their INBX share price forecasts range from $40.00 to $60.00. On average, they expect the company's share price to reach $46.50 in the next year. This suggests a possible upside of 70.6% from the stock's current price.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2022?

Inhibrx's stock was trading at $43.67 on January 1st, 2022. Since then, INBX shares have decreased by 37.6% and is now trading at $27.25.
View the best growth stocks for 2022 here
.

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our INBX earnings forecast
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) posted its earnings results on Tuesday, November, 9th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.06. The business earned $2.53 million during the quarter, compared to analyst estimates of $1 million. Inhibrx had a negative trailing twelve-month return on equity of 1,262.54% and a negative net margin of 2,628.82%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Inhibrx's stock symbol?

Inhibrx trades on the NASDAQ under the ticker symbol "INBX."

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (6.63%), BlackRock Inc. (5.03%), State Street Corp (4.68%), Vanguard Group Inc. (3.37%), Bioimpact Capital LLC (2.94%) and Tybourne Capital Management HK Ltd. (1.48%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends
.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibrx's stock price today?

One share of INBX stock can currently be purchased for approximately $27.25.

How much money does Inhibrx make?

Inhibrx (NASDAQ:INBX) has a market capitalization of $1.19 billion and generates $7.23 million in revenue each year. The company earns $-81,770,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis.

How many employees does Inhibrx have?

The company employs 106 workers across the globe.

How can I contact Inhibrx?

Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The official website for the company is www.inhibrx.com. The company can be reached via phone at 858-795-4220 or via email at amy@juniper-point.com.

This page (NASDAQ:INBX) was last updated on 12/8/2022 by MarketBeat.com Staff